KARBF Stock - Karo Pharma AB (publ)
Unlock GoAI Insights for KARBF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
Karo Pharma AB (publ) develops and markets prescription drugs and over-the-counter products for pharmacies and retail sector in Sweden, Norway, Denmark, Finland, France, Germany, Italy, rest of Europe, the United States, and internationally. It offers skin health products under the Remescar, Locobase, Decubal, and indy beauty brand names; intimate health products under the Pevaryl, Multi Gyn, Asan, and Selexid brand names; and foot health products under the Pevaryl, CCS, Nailner, and wortie brands. The company also provides pain, cough, and cold products under the Paracet, Ibux, Mollipect, and Viruseptin brand names; prescription drugs under the Burinex, Centyl, Kaleorid, and Lithionit brands; and wellness products under the nutravita, Alpha Foods, Flux, Allévo, Dosett, Dax, and Lactocare brands. It sells its products in approximately 90 countries with Europe and the Nordic region markets through direct sales organizations and a network of distributors, as well as online. The company was formerly known as Karo Bio AB (publ) and changed its name to Karo Pharma AB (publ) in March 2016. Karo Pharma AB (publ) was incorporated in 1987 and is headquartered in Stockholm, Sweden.
Visit WebsiteEarnings History & Surprises
KARBFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2022 | Jul 21, 2022 | $0.02 | — | — | — |
Q1 2022 | Feb 25, 2022 | $0.23 | $-0.48 | -308.7% | ✗ MISS |
Q4 2021 | Oct 28, 2021 | $0.05 | $0.20 | +300.0% | ✓ BEAT |
Q3 2021 | Jul 22, 2021 | $0.28 | $-0.10 | -135.7% | ✗ MISS |
Q2 2021 | Apr 21, 2021 | $0.55 | $0.24 | -56.4% | ✗ MISS |
Q4 2020 | Oct 30, 2020 | $0.44 | $0.66 | +50.0% | ✓ BEAT |
Q3 2020 | Jul 21, 2020 | $0.49 | $0.17 | -65.3% | ✗ MISS |
Q2 2020 | Apr 29, 2020 | — | — | — | — |
Q4 2019 | Nov 15, 2019 | — | $0.16 | — | — |
Q3 2019 | Jul 19, 2019 | $0.47 | $0.17 | -63.8% | ✗ MISS |
Q2 2019 | Apr 26, 2019 | — | $0.24 | — | — |
Q4 2018 | Oct 29, 2018 | $0.25 | $0.33 | +32.0% | ✓ BEAT |
Q3 2018 | Jul 19, 2018 | — | — | — | — |
Q2 2018 | Apr 26, 2018 | — | — | — | — |
Q4 2017 | Nov 2, 2017 | — | — | — | — |
Q2 2017 | May 10, 2017 | — | — | — | — |
Q4 2016 | Oct 27, 2016 | — | — | — | — |
Q3 2016 | Jul 15, 2016 | — | — | — | — |
Q2 2016 | May 12, 2016 | — | — | — | — |
Q1 2016 | Feb 12, 2016 | — | — | — | — |
Latest News
Frequently Asked Questions about KARBF
What is KARBF's current stock price?
What is the analyst price target for KARBF?
What sector is Karo Pharma AB (publ) in?
What is KARBF's market cap?
Does KARBF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to KARBF for comparison